Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy.

× No keyword cloud information.

18 in total

1. Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation.

Authors: Hyung Gyun Kim; Tran Thi Hien; Eun Hee Han; Yong Pil Hwang; Jae Ho Choi; Keon Wook Kang; Kwang-il Kwon; Bong-Hee Kim; Sang Kyum Kim; Gye Yong Song; Tae Cheon Jeong; Hye Gwang Jeong
Journal: Br J Pharmacol Date: 2011-03 Impact factor: 8.739

2. AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell.

Authors: Gang Han; Hangjun Gong; Yidong Wang; Shaowen Guo; Kun Liu
Journal: Cancer Biol Ther Date: 2015 Impact factor: 4.742

Review 3. Chemoprevention of hormone receptor-negative breast cancer: new approaches needed.

Authors: Iván P Uray; Powel H Brown
Journal: Recent Results Cancer Res Date: 2011

Review 4. Metformin and cancer: new applications for an old drug.

Authors: Taxiarchis V Kourelis; Robert D Siegel
Journal: Med Oncol Date: 2011-02-08 Impact factor: 3.064

5. Sensitizing multi drug resistant Staphylococcus aureus isolated from surgical site infections to antimicrobials by efflux pump inhibitors.

Authors: Amr A Baiomy; Ghada H Shaker; Hisham A Abbas
Journal: Afr Health Sci Date: 2020-12 Impact factor: 0.927

6. Underactivation of the adiponectin-adiponectin receptor 1 axis in clear cell renal cell carcinoma: implications for progression.

Authors: Nir Kleinmann; Wilhelmina C M Duivenvoorden; Sarah N Hopmans; Laura K Beatty; Shengjun Qiao; Daniel Gallino; Sarka Lhotak; Dean Daya; Athanasios Paschos; Richard C Austin; Jehonathan H Pinthus
Journal: Clin Exp Metastasis Date: 2013-10-05 Impact factor: 5.150

Review 7. mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).

Authors: Alejandro Vázquez-Martín; Cristina Oliveras-Ferraros; Sonia del Barco; Begoña Martín-Castillo; Javier A Menéndez
Journal: Clin Transl Oncol Date: 2009-07 Impact factor: 3.405

The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy.